Form DEF 14A - Other definitive proxy statements:
SEC Accession No. 0001140361-26-017124
Filing Date
2026-04-27
Accepted
2026-04-27 16:30:37
Documents
20
Period of Report
2026-06-10

Document Format Files

Seq Description Document Type Size
1 DEF 14A ny20063852x3_def14a.htm   iXBRL DEF 14A 659941
6 GRAPHIC logo_gyre.jpg GRAPHIC 34472
7 GRAPHIC ny20063852x3_pvpchart01.jpg GRAPHIC 209927
8 GRAPHIC ny20063852x3_pvpchart02.jpg GRAPHIC 217714
9 GRAPHIC ny20063852x3_pc01x1.jpg GRAPHIC 613105
10 GRAPHIC ny20063852x3_pc02x1.jpg GRAPHIC 651450
  Complete submission text file 0001140361-26-017124.txt   5801942

Data Files

Seq Description Document Type Size
2 INLINE XBRL TAXONOMY EXTENSION - SCHEMA gyre-20260610.xsd EX-101.SCH 3612
3 INLINE XBRL TAXONOMY EXTENSION - DEFINITION LINKBASE gyre-20260610_def.xml EX-101.DEF 3426
4 INLINE XBRL TAXONOMY EXTENSION - LABEL LINKBASE gyre-20260610_lab.xml EX-101.LAB 3732
5 INLINE XBRL TAXONOMY EXTENSION - PRESENTATION LINKBASE gyre-20260610_pre.xml EX-101.PRE 9317
25 EXTRACTED XBRL INSTANCE DOCUMENT ny20063852x3_def14a_htm.xml XML 163476
Mailing Address 12770 HIGH BLUFF DRIVE SUITE 150 SAN DIEGO CA 92130
Business Address 12770 HIGH BLUFF DRIVE SUITE 150 SAN DIEGO CA 92130 (858) 567-7770
GYRE THERAPEUTICS, INC. (Filer) CIK: 0001124105 (see all company filings)

EIN.: 562020050 | State of Incorp.: DE | Fiscal Year End: 1231
Type: DEF 14A | Act: 34 | File No.: 000-51173 | Film No.: 26901468
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)